DNA methylation cooperates with genomic alterations during non-small cell lung cancer evolution.
Gimeno-Valiente F., Castignani C., Larose Cadieux E., Mensah NE., Liu X., Chen K., Chervova O., Karasaki T., Weeden CE., Richard C., Lai S., Martínez-Ruiz C., Lim EL., Frankell AM., Watkins TBK., Stavrou G., Usaite I., Lu W-T., Marinelli D., Saghafinia S., Wilson GA., Dhami P., Vaikkinen H., Steif J., Veeriah S., Hynds RE., Hirst M., Hiley C., Feber A., Deniz Ö., Jamal-Hanjani M., McGranahan N., TRACERx Consortium None., Beck S., Demeulemeester J., Tanić M., Swanton C., Van Loo P., Kanu N.
Aberrant DNA methylation has been described in nearly all human cancers, yet its interplay with genomic alterations during tumor evolution is poorly understood. To explore this, we performed reduced representation bisulfite sequencing on 217 tumor and matched normal regions from 59 patients with non-small cell lung cancer from the TRACERx study to deconvolve tumor methylation. We developed two metrics for integrative evolutionary analysis with DNA and RNA sequencing data. Intratumoral methylation distance quantifies intratumor DNA methylation heterogeneity. MR/MN classifies genes based on the rate of hypermethylation at regulatory (MR) versus nonregulatory (MN) CpGs to identify driver genes exhibiting recurrent functional hypermethylation. We identified DNA methylation-linked dosage compensation of essential genes co-amplified with neighboring oncogenes. We propose two complementary mechanisms that converge for copy number alteration-affected chromatin to undergo the epigenetic equivalent of an allosteric activity transition. Hypermethylated driver genes under positive selection may open avenues for therapeutic stratification of patients.